0% · Initialising analytics engine

Health Economics · HTA · Market Access · GCC & MENA

Healthcare analytics, made decision-ready.

We turn fragmented health data into evidence that payers and HTA bodies can act on. The result is less uncertainty, faster approvals and more predictable access to high-value therapies.

Explore services

Our conviction

Health systems don’t lack data. They lack evidence they can act on. We turn fragmented data into insight that decisions can rest on, grounded in local reality, so the right therapies reach the right patients.

About QALYt

Why we exist, what we do, and how we work.

WHY

Better access through better evidence

We turn fragmented data into insight that decision-makers trust. That cuts uncertainty, speeds up approvals and makes access more predictable in resource-constrained systems.

WHAT

Health economics, HTA & market access expertise

HTA, HEOR, real-world evidence, analytics, pricing and managed-entry solutions, aligned with national guidelines and regional payer expectations.

HOW

Strategic consulting & system transformation

We partner with pharma companies and public-health institutions, from readiness assessment through to capability building and policy execution.

Where the name comes from

“QALYt” echoes the Quality-Adjusted Life Year: measurable patient value at the centre of every access decision.

  • Pharmaceutical companiesMarket access, reimbursement and evidence strategy.
  • Government health entitiesHTA capacity, policy and value-based transformation.

Our services

Four service lines, one evidence chain.

01

Real-World Evidence & Data Analytics

Predictive modelling, forecasting and validation for pre- and post-market decisions, plus epidemiology, burden-of-disease and public-health intervention evaluation.

  • RWE studies
  • Predictive modelling
  • Forecasting
  • Epidemiology
  • Burden of disease
02

Health Economics & Outcomes Research

Cost-effectiveness, budget impact, QALY modelling, indirect comparisons, Markov, decision-tree and microsimulation models, MCDA and uncertainty analysis.

  • Cost-effectiveness
  • Budget impact
  • Markov models
  • MCDA
  • PSA
03

Market Access & Policy Shaping

HTA dossiers and localisation, pricing and reimbursement strategy, and value communication, along with managed-entry design, policy intelligence and stakeholder advisory.

  • HTA dossiers
  • Pricing
  • Reimbursement
  • Managed entry
  • Advisory boards
04

Healthcare Evidence & Medical Writing

Systematic and rapid reviews and meta-analyses, turning clinical evidence into HTA- and payer-aligned positioning and white papers.

  • Systematic reviews
  • Meta-analyses
  • White papers
  • Payer positioning

How we work with you

From fragmented data to predictable access.

01

Understand your evidence & access landscape

Map current evidence, find gaps against local HTA and payer requirements, and analyse policy, pricing and reimbursement in target markets.

02

Build the evidence

HEOR, models, RWE and reviews, designed around local data and national guidelines.

03

Make the case

Localised dossiers, pricing and managed-entry strategies, and value communication that payers can act on.

04

Embed capability

Stakeholder engagement and capacity building so access outcomes last beyond the project.

12 capability areas

Every regional gap, matched to added value.

Select a card to see the market gap and the value of closing it.

Where we deliver

Core GCC delivery, extending across MENA.

Why regional, not global? Global evidence often falls short locally. Every model and dossier we build is grounded in local data, national guidelines and regional payer expectations.

  • Saudi Arabia
  • United Arab Emirates
  • Dubai
  • Qatar
  • Kuwait
  • Bahrain
  • Oman
  • Iraq
  • + wider MENA

FAQs

Questions & answers.

What does QALYt do?

QALYt is a health economics, HTA and market access consultancy for MENA and the GCC. We turn fragmented data into HTA dossiers, economic models, real-world evidence and pricing strategies.

What does “QALYt” mean?

The name comes from the Quality-Adjusted Life Year, which puts measurable patient value at the centre of every access decision.

Who do you work with?

Pharmaceutical companies seeking market access, reimbursement and evidence strategy; and government health entities building HTA capacity and policy.

Which countries do you cover?

Core delivery across Saudi Arabia, the UAE (including Dubai), Qatar, Kuwait, Bahrain, Oman and Iraq, extending across the wider MENA region.

Why a regional consultancy rather than a global one?

Global evidence often falls short in local contexts. Our work is grounded in local data, national guidelines and regional payer expectations.

Have a project?

Let’s build the evidence your decision needs.

Clarify any uncertainties and get a smooth, hassle-free start. Send a brief or request a quote.